Payment overview · 2025
General Payments
$846.68
47 reported records · 14 companies
Healthcare provider profile · identity verified
Dylan Koenig, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · MUNISING, MI · NPI 1780156232
Verified facts
What the public records show
CMS Open Payments records show Dylan Koenig, PA received $846.68 in general payments during 2025 across 47 reported records.
ABBVIE INC. accounted for 37.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Otezla, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Otezla by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $320.56 | 37.9% | 20 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $92.11 | 10.9% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $71.68 | 8.5% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $47.67 | 5.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $46.81 | 5.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.02 | 5.3% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $40.95 | 4.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $40.06 | 4.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.46 | 4.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.29 | 3.6% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $27.35 | 3.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.86 | 2.0% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $16.40 | 1.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.46 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $846.68 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $205.48 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $122.35 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $115.08 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $92.11 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $92.11 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $71.68 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $47.67 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $46.81 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $45.02 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $40.95 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $35.46 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $30.46 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.29 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.29 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $27.35 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $27.35 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $27.35 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $27.35 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $26.15 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $16.40 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.91 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 69 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
69 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
76 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 352 | 65 |
| Gabapentin | Gabapentin | 275 | 46 |
| Omeprazole | Omeprazole | 256 | 48 |
| Lisinopril | Lisinopril | 233 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 213 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 174 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 171 | 39 |
| Furosemide | Furosemide | 159 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 155 | 21 |
| Amlodipine Besylate | Amlodipine Besylate | 149 | 32 |
| Losartan Potassium | Losartan Potassium | 138 | 35 |
| Prednisone | Prednisone | 117 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 109 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 24 |
| Potassium Chloride | Potassium Chloride | 96 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 89 | 13 |
| Alprazolam | Alprazolam | 86 | 18 |
| Metformin Hcl | Metformin Hcl | 85 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 83 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 80 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 15 |
| Tramadol Hcl | Tramadol Hcl | 77 | 14 |
| Eliquis | Apixaban | 76 | 15 |
| Mirtazapine | Mirtazapine | 75 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 75 | 11 |
| Carvedilol | Carvedilol | 74 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 71 | 15 |
| Simvastatin | Simvastatin | 70 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 69 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 67 | 18 |
| Meloxicam | Meloxicam | 64 | 11 |
| Metformin Hcl Er | Metformin Hcl | 60 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 24 |
| Trazodone Hcl | Trazodone Hcl | 57 | 12 |
| Sertraline Hcl | Sertraline Hcl | 56 | 13 |
| Lorazepam | Lorazepam | 55 | suppressed |
| Spironolactone | Spironolactone | 53 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 50 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 49 | suppressed |
| Pregabalin | Pregabalin | 49 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 46 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | suppressed |
| Glimepiride | Glimepiride | 43 | suppressed |
| Memantine Hcl | Memantine Hcl | 43 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 40 | suppressed |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Famotidine | Famotidine | 37 | suppressed |
| Ibuprofen | Ibuprofen | 37 | suppressed |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 35 | suppressed |
| Methocarbamol | Methocarbamol | 35 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 35 | suppressed |
| Aripiprazole | Aripiprazole | 34 | suppressed |
| Lamotrigine | Lamotrigine | 33 | suppressed |
| Baclofen | Baclofen | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Fluconazole | Fluconazole | 32 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Azithromycin | Azithromycin | 30 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 30 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 15 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 19 |
| Montelukast Sodium | Montelukast Sodium | 27 | suppressed |
| Ozempic | Semaglutide | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Cephalexin | Cephalexin | 23 | 11 |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Otezla | Apremilast | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 13 |
| Methotrexate | Methotrexate Sodium | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Fluocinonide | Fluocinonide | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $846.68 · 47 records | ABBVIE INC. | AREXVY, AUSTEDO XR, Auvelity, CAPLYTA, CAPVAXIVE, ENFLONSIA, GARDASIL 9, JARDIANCE, KRYSTEXXA, MOUNJARO, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, REXULTI, SUBLOCADE, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VAXELIS, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error